In-line with Actavis’ strategy to grow and expand its Specialty Brands business globally, the Company has a commercial presence in Canada and is strengthening its presence in Latin America with organizational and regulatory milestones.
In Canada, in 2012, Actavis launched and currently markets Rapaflo®, Gelnique®, Androderm®, and Oxytrol®, and has deployed a sales force of 24 representatives calling on urologists and primary care physicians to detail these products.
Also in 2012, Actavis Specialty Brands secured an accelerated regulatory filing with Health Canada for Esmya® (ulipristal acetate), a product licensed from Gedeon Richter Plc, a potential treatment for uterine fibroids that is currently in development.
In Latin America, Actavis Specialty Brands has made significant headway for products expected to serve as the springboard for our Specialty Brands business in the region.
In 2012, Actavis filed regulatory submissions with ANVISA for approval of Rapaflo® and Gelnique® in Brazil. We are also preparing to file Androderm® for approval in Brazil and Rapaflo® and Gelnique® for approval in Mexico in 2013.